Full Title
RLY-4008-101: A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
Study Treatment
Oral FGFR2 inhibitor RLY-4008
Eligibility/Info
Groups 1-5, 7: FGFR2-altered (fusion/mutation/amplification) solid tumor without available standard therapy
Group 6: Unresectable/metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement without prior treatment in the advanced/metastatic setting
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
